Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

About one-third of children diagnosed with severe malaria may instead have an alternative cause of illness, but simple blood tests could help researchers distinguish between the two and speed up research on new treatments.

A healthcare worker with gloved hands draws blood from a child's finger. © 2020 MORU. Photographer: Gerhard Jørén.

Using simple blood tests could help researchers identify children who have been misidentified as having severe malaria, according to a study published today in eLife.

Researchers are working to develop better ways to treat severe malaria, which kills about 400,000 children in Africa each year. The discovery could help expedite such research by helping them more accurately identify children with severe malaria. It also reinforces the importance of the World Health Organization’s recommendation that all children being treated for severe malaria also receive antibiotics to ensure any misdiagnosed children receive life-saving care.

Diagnosing severe malaria in children in Africa is challenging because the parasites that cause malaria can be found in both healthy and severely ill children. This makes it difficult to tell if the parasites or some other condition is causing illness. In fact, many children diagnosed with severe malaria may have other life-threatening infections. In addition to potentially delaying life-saving antibiotic care, misdiagnosis can skew the results of studies of new treatments for malaria because children misdiagnosed with malaria will not respond, which could make drugs that work look ineffective.

“Inaccuracy in the diagnosis of severe malaria negatively impacts clinical studies, especially those trying to understand which genes may make people more vulnerable to severe disease, or which treatments are most effective,” says co-first author James Watson, Senior Scientist at the Mahidol Oxford Tropical Medicine Research Unit (MORU) in Bangkok, Thailand. “We wanted to know whether complete blood count data, notably platelet counts and white blood cell counts, could help make the diagnosis of malaria more accurate.”

Watson, along with co-first author Carolyne Ndila, a researcher at The Kenya Medical Research Institute-Wellcome Trust Research Programme (KWTRP), in Kilifi, Kenya, and their colleagues developed a statistical model that could distinguish between severe malaria and other severe illnesses that can be mistaken as severe malaria. To develop the model they included data from over 1,500 children and adults diagnosed with severe malaria in Thailand and Bangladesh. In these countries, people are rarely misdiagnosed with severe malaria because it is much less common for healthy people to have malaria parasites in their blood.

They applied this model, which relied on platelet and white blood cell counts, to a large cohort of Kenyan children diagnosed with severe malaria. Based on their analysis, they estimate that in approximately one-third of the children, severe malaria was in fact a misdiagnosis.

“Our results support the current guideline that all children with suspected malaria should be given both antimalarials and broad-spectrum antibiotics, as many of the misdiagnosed children will likely have had bacterial sepsis, a severe blood infection,” Ndila says.

Using their new model to reanalyse data from clinical studies that looked for potential genetic factors that protect against severe malaria, the team also found that people with glucose-6-phosphate dehydrogenase deficiency probably have some protection from malaria. This benefit was likely obscured in previous studies by the high rate of misdiagnoses.

“We hope our new model can be used by other scientists and clinicians to improve the accuracy of diagnosis in children suspected of having severe malaria,” concludes senior author Nicholas White, Professor of Tropical Medicine at Mahidol University. “This will help studies trying to identify better treatments for these patients.”

For full paper:

Improving statistical power in severe malaria genetic association studies by augmenting phenotypic precision. Nyutu G, Mohammed S, Ngetsa C, Mturi N, Peshu N, Tsofa B, Rockett K, Leopold S, Kingston H, George EC, Maitland K, Day NP, Dondorp AM, Bejon P, Williams T, Holmes CC, White NJ. Elife. 2021 Jul 6;10:e69698. doi: 10.7554/eLife.69698. Epub ahead of print. PMID: 34225842.

Similar stories

Congratulations Professor Sir David Warrell, appointed Knight Commander of the Order of St Michael and St George

David Warrell, our founding director, has been appointed by the Queen ‘Knight Commander of the Order of St Michael and St George for services to global Health Research and Clinical Practice’. Please join us in congratulating Sir David on receiving this richly deserved high honour!

Patient recruitment on track in Oxford-led DeTACT trial of safe, effective drug combinations to prevent the spread of artemisinin and multi-drug resistant malaria in Africa

Today is World Malaria Day. The global fight against malaria is at a critical point. No new antimalarial drugs are expected in the near future, and if multi-drug resistant falciparum malaria becomes established in East Africa and spreads to other parts of Africa, millions will be at risk of drug-resistant malaria infection and death. The development of triple artemisinin-based combination therapies aims to prevent or delay the emergence of artemisinin and multi-drug resistant malaria in Africa.

TACT-CV study shows artemether–lumefantrine plus amodiaquine an effective treatment for multidrug-resistant malaria in GMS

A triple artemisinin-based combination therapy (TACT) of artemether-lumefantrine plus amodiaquine (AL+AQ) for uncomplicated falciparum malaria in areas with a high prevalence of artemisinin resistance is a well-tolerated, effective treatment for multidrug-resistant parasites, say a team of MORU-led researchers.

Largest-ever IPD meta-analysis of malaria patients to inform haemoglobin changes

A new malaria study using a very large analysis of pooled individual patient data (IPD) from more than 70,000 patients of all ages, has been published in BMC Medicine by the WorldWide Antimalarial Resistance Network Falciparum Haematology Study Group

Study finds steady increase in WHO-validated artemisinin resistance markers in Asia

From 2002-2018, there has been a steady increase in the places and proportion of infected people reporting validated kelch13 (K13) artemisinin resistance markers, according to a study in The Lancet Microbe. This increase in artemisinin resistance threatens efforts to eliminate malaria in Asia by 2030 — and control efforts in other endemic regions. The authors say that more consistent data collection, over longer time periods in the same areas, and rapid sharing of data are needed to map the spread of resistance and better inform policy decisions.

Global Research on AntiMicrobial resistance (GRAM) project

Antimicrobial resistance (AMR) is responsible for at least 1.27 million deaths per year — with over 97,000 deaths in 2019 in SE Asia alone, according to a study published in The Lancet by the Global Research on AntiMicrobial resistance (GRAM) project, who urged urgent action from policymakers and health communities to avoid further preventable deaths.